Financial toxicity in cancer patients treated with radiotherapy in Germany—a cross-sectional study
Tóm tắt
Financial toxicity arises in cancer patients from subjective financial distress due to objective financial burden from the disease or treatment. Financial toxicity associates with worse outcomes. It has not been described in cancer patients undergoing radiotherapy in Germany and its publicly funded health system. In this context, we therefore investigated the prevalence of financial toxicity, associated risk factors, and patient preferences on communication of financial burden. We conducted a preregistered (
https://doi.org/10.17605/OSF.IO/KH6VX
) cross-sectional study surveying patients at the end of their course of radiotherapy in two institutions. Objective financial burden was assessed by direct costs and loss of income. Financial toxicity was measured by subjective financial distress per EORTC QLQ-C30. We used Spearman’s correlation and Fisher’s exact test for univariate analysis, an ordinal regression for multivariate analysis. A p-value < 0.05 was considered statistically significant. Of the 100 patients participating in the study, 68% reported direct costs, 25% loss of income, and 31% subjective financial distress. Per univariate analysis, higher subjective financial distress was significantly associated with active employment, lower quality of life, lower household income, higher direct costs, and higher loss of income. The latter three factors remained statistically significant in the multivariate analysis. A relative majority of the patients welcomed communication regarding financial burden with their radiation oncologist. Financial toxicity is prevalent in cancer patients treated with radiotherapy in Germany. The reported risk factors may help to identify patients at risk. Future studies should validate these results and investigate interventions for financial toxicity to potentially improve outcomes.
Tài liệu tham khảo
Witte J, Mehlis K, Surmann B et al (2019) Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications. Ann Oncol 30:1061–1070. https://doi.org/10.1093/annonc/mdz140
Chino F, Peppercorn J, Taylor DH et al (2014) Self-reported financial burden and satisfaction with care among patients with cancer. Oncologist 19:414–420. https://doi.org/10.1634/theoncologist.2013-0374
Perrone F, Jommi C, Maio MD et al (2016) The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. Ann Oncol 27:2224–2229. https://doi.org/10.1093/annonc/mdw433
Bernard DSM, Farr SL, Fang Z (2011) National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol 29:2821–2826. https://doi.org/10.1200/JCO.2010.33.0522
Narang AK, Nicholas LH (2017) Out-of-pocket spending and financial burden among medicare beneficiaries with cancer. JAMA Oncol 3:757–765. https://doi.org/10.1001/jamaoncol.2016.4865
Zafar SY, Peppercorn JM, Schrag D et al (2013) The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist 18:381–390. https://doi.org/10.1634/theoncologist.2012-0279
Longo CJ, Fitch MI, Banfield L et al (2020) Financial toxicity associated with a cancer diagnosis in publicly funded healthcare countries: a systematic review. Support Care Cancer 28:4645–4665. https://doi.org/10.1007/s00520-020-05620-9
Barbaret C, Brosse C, Rhondali W et al (2017) Financial distress in patients with advanced cancer. PLoS ONE 12:e176470. https://doi.org/10.1371/journal.pone.0176470
Lueckmann SL, Kowalski C, Schumann N (2021) Finanzielle Toxizität einer Krebserkrankung. Onkologe. https://doi.org/10.1007/s00761-021-00931-w
Schroeder SR, Agusala V, Sher DJ (2019) Financial toxicity and cancer therapy: a primer for radiation oncologists. Hematol Oncol Clin North Am 33:1117–1128. https://doi.org/10.1016/j.hoc.2019.08.013
Palmer JD, Patel TT, Eldredge-Hindy H et al (2018) Patients undergoing radiation therapy are at risk of financial toxicity: a patient-based prospective survey study. Int J Radiat Oncol Biol Phys 101:299–305. https://doi.org/10.1016/j.ijrobp.2018.03.014
Lievens Y, Borras JM, Grau C (2020) Provision and use of radiotherapy in Europe. Mol Oncol 14:1461–1469. https://doi.org/10.1002/1878-0261.12690
Foster ED, Deardorff A (2017) Open science framework (OSF). J Med Libr Assoc 105:203–206. https://doi.org/10.5195/jmla.2017.88
Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376. https://doi.org/10.1093/jnci/85.5.365
Fayers P, Aaronson NK, Bjordal K et al (2001) EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels
Meisenberg B, Varner A, Ellis E et al (2015) Patient attitudes regarding the cost of illness in cancer care. Oncologist 20:1199–1204. https://doi.org/10.1634/theoncologist.2015-0168
Bender R, Lange S (2001) Adjusting for multiple testing—when and how? J Clin Epidemiol 54:343–349. https://doi.org/10.1016/S0895-4356(00)00314-0
Mehlis K, Witte J, Surmann B et al (2020) The patient-level effect of the cost of cancer care—financial burden in German cancer patients. BMC Cancer 20:529. https://doi.org/10.1186/s12885-020-07028-4
Büttner M, König HM, Löbner M et al (2019) Out-of-pocket-payments and the financial burden of 502 cancer patients of working age in Germany: results from a longitudinal study. Support Care Cancer 27:2221–2228. https://doi.org/10.1007/s00520-018-4498-1
Koskinen JP, Färkkilä N, Sintonen H et al (2019) The association of financial difficulties and out-of-pocket payments with health-related quality of life among breast, prostate and colorectal cancer patients. Acta Oncol 58:1062–1068. https://doi.org/10.1080/0284186X.2019.1592218
Lauzier S, Lévesque P, Mondor M et al (2013) Out-of-pocket costs in the year after early breast cancer among Canadian women and spouses. J Natl Cancer Inst 105:280–292. https://doi.org/10.1093/jnci/djs512
Esselen KM, Gompers A, Hacker MR et al (2021) Evaluating meaningful levels of financial toxicity in gynecologic cancers. Int J Gynecol Cancer 31:801–806. https://doi.org/10.1136/ijgc-2021-002475
Fenn KM, Evans SB, McCorkle R et al (2014) Impact of financial burden of cancer on survivors’ quality of life. J Oncol Pract 10:332–338. https://doi.org/10.1200/JOP.2013.001322
Hong Y‑R, Salloum RG, Yadav S et al (2020) Patient-provider discussion about cancer treatment costs and out-of-pocket spending: implications for shared decision making in cancer care. Value Health 23:1592–1598. https://doi.org/10.1016/j.jval.2020.08.002
Kale HP, Carroll NV (2016) Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer 122:283–289. https://doi.org/10.1002/cncr.29808
de Souza JA, Yap BJ, Wroblewski K et al (2017) Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer 123:476–484. https://doi.org/10.1002/cncr.30369
Prasad RN, Patel TT, Keith SW et al (2021) Development of a financial toxicity screening tool for radiation oncology: a secondary analysis of a pilot prospective patient-reported outcomes study. Adv Radiat Oncol 6:100782. https://doi.org/10.1016/j.adro.2021.100782